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ABSTRACT
Design of the study: a cross-sectional population-based study performed at clinics and healthy units at
Curitiba - Paraná - Brazil.
Objectives: to evidence which are the major cardiovascular risk factors of MS related with the hepatic
steatosis (HS).
Methodology: 75 patients with metabolic syndrome (MS), in treatment or not for this condition, after
meeting the criteria of inclusion or exclusion for the research, were submitted to ultrasound exam of the
liver to quantify the degree of HS. Then, the relationship between HS and cardiovascular risk factors of MS
was evaluated.
Results: regardless of age, gender and hypertension, patients with glucose intolerance or diabetes
mellitus have a higher risk for HS than patients with normal serum glucose (p<0,05). Less relevant,
hypertension also demonstrated association with HS.
Conclusions: Cardiovascular risk factors of MS may be associated with HS. The alteration of glucose
metabolism appears to be the main risk factor of MS associated with HS.
Keywords: Metabolic Syndrome X. Fatty Liver . Risk Factors / Cardiovascular Diseases. Ultrasonic Imaging.
Diabetes Mellitus, Type 2. Insulin Resistance.
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1. Introduction
The relationship between metabolic syndrome
(MS) and non-alcoholic fatty liver disease (NAFLD)
has become increasingly recognized. In this context,
hepatic steatosis (HS), also called fatty liver, is the
main example of this relationship. It has been sug-
gested that liver disease is not a modest marker of
cardiovascular disease, but also a contributing factor
for its development.1,2
MS is defined as a complex disorder represented
by a set of cardiovascular risk factors usually associ-
ated to the central deposition of fat and insulin resist-
ance.3 The features of MS are: abdominal obesity,
atherogenic dyslipidemia (elevated triglycerides and
small particles of low-density lipoprotein cholesterol
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[LDL-c], low high-density lipoprotein cholesterol
[HDL-c]), insulin resistance and increased blood pres-
sure.1-5
However, no one know for sure (although there
are several hypothesis) why patients with MS are at
higher risk for NAFLD. Probably, the mechanism of
liver injury consists in the abnormality of glucose and
lipid metabolisms. The alterations of lipid metabolism
are the increased liver input and biosynthesis of free
fatty acids.1,2,6
NAFLD, the most common chronic liver dis-
ease, is characterized by increased deposition of
triglycerides in hepatocytes.1,2,7,8 HS is the main rep-
resentative of this entity.
The connection between liver injury and in-
creased cardiovascular risk can be demonstrated
through several examples in the literature. Patients in
this condition commonly have intra-abdominal visceral
fat in excess and inflammatory changes in adipose tis-
sue, closely related features to atherosclerosis.1,2
This study was based in the analysis of the im-
portance of each MS risk factor supposed to partici-
pate in liver injury, represented mainly by HS. Then,
the knowledge of which MS component impairs liver
function in a higher degree is fundamental for
optimizing treatment.
2. Objective
To define the main cardiovascular risk factors
of MS related to HS.
3. Material and methods
Study Design
A cross-sectional population-based study, whose
target population are adults having 30 to 80 years of
age, of both genders, living at Curitiba, Paraná, Brazil.
The data analysis was performed qualitatively.
Sampling Plan
Sample composed by 75 patients, all with MS
according to the diagnostic criteria of NCEP-ATPIII
(National Cholesterol Education Program - Adult
Treatment Panel III)3, even if they are treating some
or all of its factors. The patients were included in the
research regardless having or not HS, because this
condition was further evaluated by liver ultrasound.
Procedure for data collection
The research was approved by Comitê de Ética
em Pesquisa em Seres Humanos do Setor de Ciências
da Saúde da Universidade Federal do Paraná.
The patients were selected, after observing the
inclusion and exclusion criteria (Table 1), at clinics and
healthy units at Curitiba, Paraná by physicians and
medical students of Pontifícia Universidade Católica
do Paraná. After being selected, they were included
in the research signing the Statement of Consent, and
then answered the questionnaire. The questions were
about personal information of the patients (full name,
phone number, age, gender, weight, height, Body Mass
Index) and clinic factors that are components of MS
(blood pressure, fasting glucose, triglycerides, HDL-c
and waist circumference). Therefore, the question-
naire was completed after the quantification, clinical
or laboratorial, of the cardiovascular risk factors of
this syndrome.
Table 1
 Inclusion and exclusion criteria of patients
Inclusion criteria
1) To present or to be in treatment for at least three of the
defining criteria for metabolic syndrome:
- Diabetes mellitus or fasting glucose above 100 mg/
dL;
- Hypertension or blood pressure greater than or equal
to 130x85 mmHg;
- Triglyceride value greater than or equal to 150 mg/dL;
- HDL-c less than 40 mg/dL for men and less than 50
mg/dL for women;
- Waist circumference greater than 102 centimeters for
men and greater than 88 centimeters for women.
2) Age between 30 and 80 years.
Exclusion criteria
- Present or be in treatment for any autoimmune, metal
deposition or chronic viral liver disease;
- Be in treatment with potentially hepatotoxic medica-
tion for na illness unrelated to the cardiovascular sys-
tem;
- Positive serology for hepatitis B or C;
- Established coronary disease;
- Symptoms suggestive of angina pectoris or medical
history of coronary atherosclerosis;
- Alcohol intake greater than 20 grams per day.
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The blood pressure measurement was done
according to the brazilian guideline of arterial hyper-
tension (V Diretrizes Brasileiras de Hipertensão Ar-
terial - V Brazilian Guideline of Hypertension).9 The
mensuration of the waist circumference was performed
with tape line (standardized among researches) with
the patient in orthostatic position, and was considered
increased in men when exceeded 102 centimeters and
in women when exceeded 88 centimeters.4
The serum glucose and the lipidogram were
evaluated after blood collection at healthy units (near-
est to their houses) and measured at Laboratório Mu-
nicipal de Curitiba. The serum glucose was consid-
ered abnormal when exceeded 100mg/dL (regardless
if exceeded or not 126mg/dL, characterizing diabetes
mellitus or intolerance to glucose).3,4 The HDL-c was
considered low when below 40mg/dL in men and be-
low 50mg/dL in women. Elevated triglycerides was
considered when over 150mg/dL.3,4
Serology screening for hepatitis B and C, through
Anti-HCV, Anti-HBs and HBsAg was also performed.
Ultrasonic imaging
Once selected, each patient was subjected to
real-time ultrasonic imaging after at least six hours of
fasting (to reduce intestinal gas and to prevent con-
traction of the gallbladder) with a curved transducer
and appropriate intercostal approach (frequency of 2.5
to 5 MHz). The images were obtained in supine posi-
tion and right anterior oblique and/or left lateral decu-
bitus. Furthermore, images were acquired during apnea
to improve the visualization of the hepatic dome.
The defining ultrasound finding of HS was the
liver increased echogenicity.10
Statistical analysis
Results were expressed as means and stand-
ard deviations (quantitative variables) or as frequen-
cies and percentages (categorical variables). To evalu-
ate the association of dichotomist categorical variables
with the presence or not of HS, the Fisher's exact test
was considered. For the assessment of age was used
Student's t test for independent samples.
In a multivariate analysis a Logistic Regression
model was adjusted, considering Wald's test for deci-
sion-making about the included factors in the model.
After adjusting, the values for odds ratio (OR) and cor-
responding confidence interval of 95% were estimated.
P values <0.05 were considered statistically significant.
The data were organized into an Excel spreadsheet
and analyzed with the software Statistica v.8.0.
4. Results
The sample comprises 75 30 to 80 years old
patients (55 women and 20 men), all with MS.
Forty and two patients (56%) had altered glu-
cose levels (glucose intolerance or diabetes mellitus).
Of these, 35 (nearly 83%) showed HS, in the hepatic
ultrasound exam (p value= 0.025, regardless the se-
verity of this condition). However, considering the
patients that did not have glucose alteration (33 sub-
jects, 44% of total sample), about 60% had fatty liver
damage in the exam.
Arterial hypertension also proved being one of
the main risk factors of MS associated to HS devel-
opment. This is explained by the fact of, under statis-
tic analysis, this information revealed marginal tendency
close to positivity, both in univariate (Table 2) and in
multivariate (Table 2) statistics. Accordingly, about
78% of the patients with increased blood pressure
(above 130x85 mmHg or under pharmacological treat-
ment for hypertension), had liver injury confirmed by
ultrasonic imaging.
Data for waist circumference were not analyzed
because almost all patients exhibited increased values
(above 102 centimeters for men and above 88 cen-
timeters for women).
5. Discussion
It is evident in the literature that there is a cor-
relation between the development of NAFLD and MS.
Through pathophysiological mechanisms not yet well
understood, but which are interconnected, is discussed
that both conditions are spectrum of the same disease.1
Metabolic Syndrome and fatty liver injury
MS is a range of risk factors that, interre-
lated, would be directly involved in the development
of atherosclerotic cardiovascular disease. This group
of metabolic disorders includes the following patho-
physiologic process: obesity state (especially increased
abdominal circumference), insulin resistance with or
without glucose intolerance, hyperinsulinemia, dyslipi-
demia and prothrombotic and pro-inflammatory
states.1-5,8,11,12,13
As mentioned, it is not fully elucidated how these
factors trigger disease onset. It is believed that MS
has three relevant etiologic factors: obesity and the
fat tissue functional alteration, peripheral insulin re-
sistance and independent factors produced in the liver
or in the immune or vascular systems.1,2,8,13
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Table 3
Multivariate analysis: including factors with p<0.25 in the univariate analysis
Variable p value Risk classification OR Lower limit Upper limit
Age 0.982 x 1 0.94 1.06
Gender 0.782 x 0.84 0.24 2.97
Glycemia 0.047 GI or DM 3.19 1 10.27
Hypertension 0.061 Yes 4.06 0.91 18.07
OR = Odds Ratio; GI = Glucose intolerance; DM = Diabetes mellitus
Table 2
Univariate analysis of risk factors for metabolic syndrome and its relevance for the development of hepatic
steatosis
n (%) n (%)
Variable Classification n Without steatosis 20 With steatosis 55 p value
Gender Female 55 14 (25.4) 41 (74.6)
Male 20 6 (30.0) 14 (70.0) 0.770
Age Years X 52.4 ± 11.9 55.5 ± 9.6 0.256
Glycemia Normal 33 13 20
Increased 42 7 35 0.025
Triglycerides Normal 23 7 16
Increased 52 13 39 0.778
Hypertension Absent 11 6 5
Present 64 14 50 0.058
Normal 16 4 12
HDL-c Low 58 16 42 1.000
HDL-c = High-density lipoprotein cholesterol;
Fisher’s exact test or chi-square test, p<0.05; P=0.256 (Student’s t test for independent samples)
Visceral obesity leads to an ectopic deposit of
fat tissue. This visceral adipose tissue allows an in-
creased flux of free fatty acids, and can be consid-
ered an endocrine organ. This is evidenced by the
capacity of hormone and pro-inflammatory cytokines
production, including tumor necrosis factor-alpha,
which is an important mediator of insulin resistance
associated to obesity. Consequently, leads to a signifi-
cant decrease of glucose transporters functionally
available.1,2,5,7,8,12-16
Insulin resistance, considered the main factor,
seems to act as a regulatory element of our body, try-
ing to block the gain fat, producing a higher quantity
of insulin. Nevertheless, maintaining this mechanism
is pathogenic to own metabolism. This hyperinsuline-
mic state is pro-inflammatory and atherogenic. The
Medicina (Ribeirão Preto) 2012;45(4): 445-51
http://revista.fmrp.usp.br
449
Knopfholz J, Marques GR, FernandesTA, Seleme VB, Disserol CCD.
Characteristics of metabolic syndrome associated with hepatic steatosis
pro-inflammatory condition associated to other fac-
tors, such as hypertension and dyslipidemia, can cause
endothelial damage. In turn, this endothelial dysfunc-
tion caused by increased oxidative stress, results in a
reduced amount of endothelial nitric oxide, which in-
creases the vascular injury and, consequently, the pro-
gression of atherosclerosis.8,11,13,14,15,17-20
Therefore, there is a dysfunction state of the
metabolism and, the liver, as responsible for the
processing of fatty acids through their uptake, oxida-
tion or metabolism, also suffers the consequences of
this imbalance.21 This change would be translated by
NAFLD onset.5,7,8,12,14,15,22
The relationship of these two entities has been
showed in this study. Based on a total sample of 75
patients with MS, approximately 73% of the subjects
had HS. These values corroborate the literature and
make us believe that, possibly, HS and MS are com-
ponents of the same disease and insulin resistance is
his great precursor.
Insulin resistance and NAFLD
Insulin resistance is considered by Hermes et
al13 as the MS epicenter. According to him, "the insu-
lin resistance reflects the insulin inability to promote
glucose metabolism homeostasis." The clinical trans-
lation of this change is the appearing of impaired fast-
ing glucose, a component of the diagnostic criteria for
MS. Insulin also plays a role in lipids and proteins
metabolism.7,8,13 Lipids have in their composition free
fatty acids, and, in obese individuals, there is an in-
creased mobilization and oxidation of these acids in
the tissues sensitive to insulin.7,16 In the liver, the free
fatty acids metabolism increases gluconeogenesis. In
the muscles, the increased oxidation results in insulin
resistance. As outcomes of these changes hyperglyc-
emia and hyperinsulinemia are established.7,8,11,16
Hyperinsulinemia associated to insulin resistance
can contribute to HS induction, because eventually it
will increase mitochondrial oxidation of fatty acids that
will be accumulated in the liver. As free fatty acids
excess is toxic to hepatocytes, they lead to inflamma-
tion (pro-inflammatory cytokines release, particularly
tumor necrosis factor-alpha) and fibrosis.23
In this study, 56% of patients had impaired fast-
ing glucose (translated as diabetes or glucose intoler-
ance). Of these, about 83% had HS (p= 0,025). Thus,
insulin resistance, fundame ntal and well described
mechanism of liver injury in patients with MS1,2,5,13,16,23,
proved being essential, as well, in this project.
Arterial hypertension and NAFLD
As a consequence of the pathophysiological
mechanism already mentioned, besides obesity and
insulin resistance, hypertension also appears to influ-
ence the onset of NAFLD in patients with MS.24 It is
known that the accumulation of abdominal fat con-
tribute to the emergence of insulin resistance, although
the mechanisms are not fully understood.1,16 Donati
et al25 considered that hypertension may result from
insulin resistance state, and that about 50% of patients
with hypertension have insulin resistance and hyper-
insulinemia. The hyperinsulinemia culminates in two
changes: increased sympathetic activity mediated by
changes in the renin-angiotensin system16 and in-
creased sodium tubular reabsorption (which induces
peripheral vascular resistance increment, that proceeds
with increased blood pressure).26
Endothelial damage appears to lead to a range
of disorders, including the generation of reactive oxy-
gen species, which are fundamental in the pathophysi-
ology of NAFLD.17-20
Donati et al25 proved a higher prevalence of
fatty liver damage in patients with hypertension (30,9%)
than in control patients (12,7%). However, the liver
fat injury is associated to obesity and the insulin re-
sistance occurs most frequently in patients with hy-
pertension.24
Thereby, the research in discussion presented
about 85% prevalence of hypertension in the studied
population. This cardiovascular risk factor also pre-
sented highlighted regarding HS, because 78% of hy-
pertensive patients had fatty liver injury (with a ten-
dency to statistical significance).
Study limitations
The project was developed with a sample of 75
patients, considered small to be used as basis for an
entire population. Thus, studies with larger numbers
of patients should be done to be used as references in
daily clinical practice.
The liver ultrasonic imaging, by the cost-effec-
tiveness and accessibility, was the method of choice
for the analysis in this study. When compared with
others imaging studies, such as computed tomography
and magnetic resonance imaging, it better assesses
diffuse fatty changes. Nevertheless, the accuracy is
markedly low when less than 33% of hepatocytes are
committed by NAFLD, what may underestimate the
results. Sensitivity and specificity of ultrasound exam
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is much lower than liver biopsy.21,27 Although the gold
standard test is the liver biopsy, it was not used in this
project because it is rarely used in clinical practice for
the analysis of NAFLD.
Data analysis was performed as qualitative sta-
tistic. If the project was analyzed in a quantitative sta-
tistic manner, likely p values would be smaller and fur-
ther statistically relevant (p<0,05).
6. Conclusion
Cardiovascular risk factors of MS may be in-
volved in the development of HS. Regardless of age,
gender and presence of arterial hypertension, patients
with glucose intolerance or diabetes mellitus are more
likely for having HS than patients with normal glucose
levels.
RESUMO
Modelo do estudo: estudo transversal de base populacional realizado em ambulatórios e unidades de
saúde em Curitiba - Paraná - Brasil.
Objetivo: evidenciar quais são os principais fatores de risco cardiovascular da síndrome metabólica
(SM) associados à esteatose hepática (EH).
Metodologia: 75 pacientes com SM, sob tratamento ou não, após preencher os critérios de inclusão ou
exclusão da pesquisa, foram submetidos à ultrassonografia hepática para investigar a presença de EH.
Em seguida, foi avaliada a relação entre EH e fatores de risco cardiovasculares da SM.
Resultados: independente da idade, gênero e hipertensão arterial, pacientes com intolerância à glicose
ou diabetes mellitus têm maior risco de EH que os pacientes com glicose sérica normal (p<0,05).
Menos relevante, hipertensão também demonstrou associação com EH.
Conclusão: fatores de risco cardiovasculares da SM podem estar associados à EH. A alteração no
metabolismo da glicose parece ser o fator fisiopatológico mais importante associado ao dano hepático.
Palavras-chave: Síndrome X Metabólica. Esteatose Hepática. Fatores de Risco  / Doenças Cardiovas-
culares. Ultrassonografia. Diabetes Mellitus Tipo 2. Resistência à Insulina.
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